Furthermore, based on the expression profile data, the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to predict the relationship between HIF‐2α expression and RCC patient response to immune checkpoint inhibitors (ICIs). The gene discussed is EPAS1; the disease is renal cell carcinoma.